|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 47/68 | (2017.01) |
| A61K 39/39 | (2013.01) | ||
| A61K 39/39 | (2006.01) | ||
| A61K 47/6849 | (2017.08) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 47/6855 | (2017.08) | ||
| A61P 35/02 | (2006.01) | ||
| A61K 31/4745 | (2013.01) | ||
| A61P 35/04 | (2006.01) | ||
| A61K 47/6803 | (2017.08) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 35/04 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Patento numeris | 2874651 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13820359.1 |
| Europos patento paraiškos padavimo data | 2013-07-16 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-05-27 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-05-24 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CN2013/079441 |
| Data | 2013-07-16 |
| (87) | Numeris | WO 2014/012479 |
| Data | 2014-01-23 |
| (30) | Numeris | Data | Šalis |
| 201210248481 | 2012-07-18 | CN |
| (72) |
LI, Lixin , CN
|
| (73) |
Birdie Biopharmaceuticals Inc. ,
4th Floor, Harbour Place
103 South Church Street
P.O. Box 10240, Grand Cayman, KY1-1002,
KY
|
| (54) | COMPOUNDS FOR TARGETED IMMUNOTHERAPY |
| COMPOUNDS FOR TARGETED IMMUNOTHERAPY |